Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amunix has signed a research and option agreement with Biogen Idec to research and develop new fully-recombinant blood factors (Factors IX, VIII and VIIa) with improved therapeutic properties.
Subscribe to our email newsletter
As per the terms of the agreement, both the parties will together organize preclinical research.
The collaboration will combine Amunix’s protein half-life engineering expertise, based on its proprietary XTEN technology, and Biogen Idec’s capabilities in research, manufacturing and clinical development of recombinant blood factors for hemophilia.
Biogen Idec will take up the responsibility for clinical development, manufacturing and commercialization of therapeutic candidates selected for further development.
Biogen Idec will be responsible to pay an initial upfront payment and R&D funding to Amunix.
In addition to that, Biogen Idec will also pay future milestone and royalty payments to Amunix for therapeutic candidates chosen by the company for development.
Biogen Idec Hemophilia senior vice president Glenn Pierce said in addition to advancing their current late-stage Factor IX and Factor VIII programs, they continue to invest in innovations like XTEN, which have the potential to bring further-improved treatment options to the hemophilia community.